Novel Treatment Advances and Approaches in the
Management of Relapsed/Refractory Multiple Myeloma

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session at the 2017 Spring Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from June 15, 2017 to August 1, 2018

Instructions for CME/CNE: Complete the pre test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This educational activity is supported by educational grants from
AbbVie, Inc., and Amgen

Multiple myeloma is a systemic malignancy of plasma cells that is highly treatable but rarely curable and the stage of the disease at presentation is a strong determinant of survival. Treatment selection is influenced by patient age and general health, prior therapy, and the presence of complications of the disease. Treatment is directed at reducing the tumor cell burden and reversing any complications of disease, such as renal failure, infection, hyperviscosity, or hypercalcemia with appropriate medical management. Unfortunately, multiple myeloma remains a disease with poor long-term survival as it is currently incurable and all patients will eventually relapse, underlining the need for new therapies. Thankfully several drugs have recently been approved, including combination therapies, for relapsed or refractory multiple myeloma. These options have shown great promise in their ability to improve clinical outcomes and include the next-generation proteasome inhibitor carfilzomib, and next-generation immunomodulatory agent pomalidomide.

Upon Completion of this activity, participants will be able to:

  • Analyze the safety and efficacy of current and emerging treatments for patients with relapsed or refractory multiple myeloma

  • Identify the best second-line treatment option for patients based on the current evidence, prior therapy, and patient characteristics such as age, comorbidity, and other risk factors

  • Implement data-driven treatment regimens to optimally manage patient-specific disease and improve outcomes for patients with relapsed or refractory multiple myeloma

  • Examine disease monitoring and supportive care strategies for patients with relapsed or refractory multiple myeloma

  • Discuss challenges clinicians encounter when managing relapsed or refractory multiple myeloma and discuss evidence-based strategies to overcome these barriers

Faculty: Ravi Vij, MD
Washington University School of Medicine
Associate Professor of Medicine
Division of Medical Oncology


Dr. Vij receives research funding from Onyx and Takeda; honoraria from AbbVie, Amgen, Bristol Myers Squibb, Celgene, Janssen, Karyopharm Therapeutics, Merck, Millennium, Sanofi and Seattle Genetics. His presentation will include off label use(s) of available drugs. His presentation has been peer reviewed.
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Will Williams has no real or perceived financial relationships to disclose.
Katie Eads has no real or perceived financial relationships to disclose.
Jacquelyn Smith has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation

The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM. Each physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This educational activity is supported by educational grants from
AbbVie, Inc., and Amgen

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue